Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring blaNDM and blaOXA From Clinical Origin
Hasan Ejaz,Mahtab Ahmad,Sonia Younas,Kashaf Junaid,Khalid Omer Abdalla Abosalif,Abualgasim Elgaili Abdalla,Ayman Ali Mohammed Alameen,Mohammed Yagoub Mohammed Elamir,Syed Nasir Abbas Bukhari,Naveed Ahmad,Muhammad Usman Qamar
DOI: https://doi.org/10.2147/IDR.S310478
2021-05-26
Infection and Drug Resistance
Abstract:Hasan Ejaz, 1 Mahtab Ahmad, 2 Sonia Younas, 3 Kashaf Junaid, 1 Khalid Omer Abdalla Abosalif, 1 Abualgasim Elgaili Abdalla, 1 Ayman Ali Mohammed Alameen, 1 Mohammed Yagoub Mohammed Elamir, 1 Syed Nasir Abbas Bukhari, 4 Naveed Ahmad, 5 Muhammad Usman Qamar 2 1 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Al Jouf, 72388, Saudi Arabia; 2 Department of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 3 Department of Pathology, Tehsil Headquarter Hospital Kamoke, Kamoke, 50661, Pakistan; 4 Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Aljouf, 72388, Saudi Arabia; 5 Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Aljouf, 72388, Saudi Arabia Correspondence: Muhammad Usman Qamar Department of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, 38000, Pakistan Email Background: The therapeutic management of carbapenem-resistant Acinetobacter baumannii (CR-AB) represents a serious challenge to the public health sector because these pathogens are resistant to a wide range of antibiotics, resulting in limited treatment options. The present study was planned to investigate the clonal spread of CR-AB in a clinical setting. Methodology: A total of 174 A. baumannii clinical isolates were collected from a tertiary care hospitals in Lahore, Pakistan. The isolates were confirmed by VITEK 2 compact system and molecular identification of rec A and bla OXA-51 . Antimicrobial profile and the screening of carbapenem-resistant genes were carried out using VITEK 2 system and PCR, respectively. The molecular typing of the isolates was performed according to the Pasteur scheme. Results: Of the 174 A. baumannii isolates collected, the majority were isolated from sputum samples (46.5%) and in the intensive care unit (ICU, 75%). Among these, 113/174 (64.9%) were identified as CR-AB, and 49.5% and 24.7% harbored bla OXA-23 and bla NDM-1 , respectively. A total of 11 (9.7%) isolates co-harbored bla OXA-51 , bla NDM-1 , and bla OXA-23 . Interestingly, 46.9% of the CR-AB belonged to sequence type 2 (ST2; CC1), whereas 15.9% belonged to ST1 (CC1). All of the CR-AB isolates showed extensive resistance to clinically relevant antibiotics, except colistin. Conclusion: The study concluded CR-AB ST2 clone harboring bla OXA-23 and bla NDM-1 are widely distributed in Pakistan's clinical settings, which could result in increased mortality. Strict compliance with the National Action Plan on Antimicrobial Resistance is necessary to reduce the impacts of these strains. Keywords: Acinetobacter baumannii , bla OXA , bla NDM , MIC, MLST The development and spread of carbapenem-resistant Acinetobacter baumannii (CR-AB) represents a serious global public health dilemma. 1 Extensively drug resistant A. baumannii produce resistance to all or almost all medically approved antibiotics. 2 A. baumannii can cause severe infections, such as septicemia, urinary tract infections, wound infections, and ventilator-associated pneumonia, and A. baumannii has been associated with nosocomial infections. 3 A. baumannii has been designated as a global priority pathogen by the World Health Organization (WHO) 4 and is listed as an ESKAPE pathogen, which effectively resist to various antibacterial drugs, and restricting therapeutic options. 5 Every year, over 0.7 million people die from infections due to antimicrobial-resistant (AMR) bacteria globally. By 2050, an individual is estimated to die from infection with an AMR pathogen every 3 seconds, and the global costs associated with AMR infections are expected to reach $100 trillion. 6 The Centers for Disease Control and Prevention has reported that CR-AB is responsible for 700 mortality, and $281 million are spent on the therapeutic management of CR-AB infections annually. 7 CR-AB develop resistance through numerous mechanisms, such as the production of β-lactam enzymes, porin proteins loss, and efflux pump overexpression. 8 Infect -Abstract Truncated-
pharmacology & pharmacy,infectious diseases